Research into cloned human cells has left the spectre of past scientific fraud behind. But reaction to the earlier work still holds worthwhile lessons.
The cells presented this week have an 23 extra chromosomes from the egg. Hwang, like most researchers in the field, removed this DNA and used the egg merely to drive reprogramming; it didn't work. The latest study left the egg DNA in, and says that some element of it is essential.
The cells derived from this 'triploid' embryo show many of the functions of normal cells, but such embryos are not viable and it is not yet clear how triploid cells would mimic the behaviour of cells in tissue. No one will be calling them clinically relevant any time soon. Still, iPS cell work is on the defensive, and this study provides proof that human somatic cells can be reprogrammed. Now, researchers have to prove that the work is a step towards a biomedically useful stem-cell line. The authors are confident that they can produce a stem-cell line from a 'normal' diploid cloned embryo, as Hwang claimed to do. They will have to work out what it is in the egg's genetic material that is necessary for the reprogramming.
The latest achievement points in the same direction as Hwang's claims. If researchers were to find the magic element in the egg, not only would there again be excitement, but the old ethical issues would resurface. Hype around potential procedures would increase the market for eggs, which is perhaps hard to justify. The embryos would be viable, no doubt again producing fears of self-cloning dictators. (For that reason, this might be a good time for the United Nations to hammer out cloning regulations or restrictions, which have been hamstrung by political and religious debate.) And desperate patients would find doctors ready to give them unproven and unsafe embryonic-stem-cell treatments.
The results might look mundane. But the potential for reasoned excitement and irrational hype remain. ■ W hen, in 2004, Woo Suk Hwang claimed to have produced a stem-cell line derived from an embryonic human clone, his research, done at Seoul University, sparked intense interest and hype. Even though Hwang's work later proved to be fraudulent, all advances in the field risk being measured against it. At the same time, researchers seek to distance themselves from the episode to the extent that its ethical implications for current work are rarely discussed.
This week, scientists have come the closest of any so far in emulating Hwang's claimed results: on page 70, researchers from the New York Stem Cell Foundation Laboratory report using cloning technology to reprogram human DNA taken from an adult and create embryonic stem cells. But they do not use the term cloning to describe their results. That is one of many contrasts between the research landscape now and in 2004.
Hwang's claims received worldwide attention. Patient groups jumped for joy; scientists around the world used the results to gather more funds for stem-cell research; and bioethicists emerged to justify or condemn the work. Reaction this week is likely to be more muted.
Discussion of the ethical concerns raised by such work have calmed, and the research group behind the latest study dealt with one of the most divisive issues -the retrieval of human eggs from donorsin a transparent and considered way. Hwang, by contrast, had procured eggs unethically and illegally, a problem first brought to public attention in Nature (see Nature 429, 3; 2004). Whereas discussion of Hwang's results featured the phrase 'therapeutic cloning' and so invited (sometimes wilful) confusion with reproductive cloning and the spectre of technology misuse, the latest paper refers only to the reprogramming of cells to a pluripotent state. A final issue -that embryos are destroyed in the process of the research -does still apply.
The ultimate goal of such research is to create patient-specific stem cells for drug screening and the growth of genetically identical tissue for transplantation. Yet cloning, whether called that or not, is no longer the only means to this end, as it seemed in Hwang's time. Induced pluripotent stem (iPS) cells, first developed in 2006, now offer the same promise without the need for egg recruitment or embryo destruction: they are produced from adult cells by introducing a few genetic factors to the cell rather than using an entire egg. When therapeutic-cloning studies stalled on an egg shortage, iPS cell frenzy filled the gap. Competition between the approaches is fierce, and the authors of the current study point out the many weaknesses of iPS cells to bolster their own work. But their approach, too, has a long way to go.
The biggest reason that the results won't generate Hwang-like headlines is that they do not go as far. go.nature.com/xhunqv discussed on page 16, reveals the commission's admirable and much-needed attempt to make applying for funding and participating in the programme a lot easier for researchers.
It is true that the commission has attempted to streamline past programmes, notably the current Seventh Framework Programme, which runs until 2013. But wider and deeper change is needed -particularly, as the commission now suggests, to harmonize the criteria for evaluating research proposals and judging what counts as eligible research costs across the different sections of the programme. This means that researchers will need to learn only one set of rules, whether they apply for funding for collaborative research projects that tackle key societal challenges such as energy efficiency, or for grants from, for example, the Budapest-based European Institute of Innovation and Technology.
The proposals also suggest the provision of better guidance for researchers who must fill out time sheets to satisfy the commission's demand for financial accountability once research projects are complete. Significantly, the plans abolish time recording for researchers who work full-time on one project, such as those with grants from the European Research Council, which funds frontier research across Europe. This comes as a welcome move, as there is little point in having all that money available if the rules of play are so complicated and time-consuming that they discourage researchers from applying. The cream of Europe's science crop have, in the past, turned their backs on the funding programme to compete for other, less-bureaucratic funding streams, threatening to push the Framework programme towards mediocrity.
There is no guarantee that the revisions go far enough to halt this trend. And as the finer details of the programme are hammered out, including developing the annual calls for proposals, the commission should allow researchers more freedom to draw up research proposals, rather than continuing to prescribe the precise projects that it wants to fund. It is scientists, not Brussels bureaucrats, who are best placed to know what is new and interesting.
Missing from the leaked proposals is a clear solution to the tension building among the 12 newest European member states -known as the EU 12, including Poland and Romania -which feel excluded by the drive to fund excellent science. With weaker national science and technology systems, researchers in these countries often lose out to their counterparts in the scientifically stronger nations, who are able to write better grant proposals. Researchers in the EU 12 complain that young research talent is not being given the support or the opportunity to show its potential. They are not alone in their concerns over the uneven geographical distribution of the programme's funds.
Members of the European Parliament's industry, research and energy committee said in a report on 31 August that they find it unacceptable that the lion's share of research funds goes to the richer member states. Traditionally, the commission allocates support for national capacity-building through a separate funding stream available in the European Union's budget, called structural funds. The commission encourages their use for research purposes in the newer member states. But it has had mixed results, in part because governments prefer to use the funds for improvements that their voters can see and use, such as new roads. It is not enough for the commission to claim that structural funds can help to put newer member states on the path towards excellent science, as it does in the Horizon 2020 draft. Rather, it must propose concrete initiatives and reforms that encourage those governments to use these funds for research. A key starting point could be to cut the red tape around the use of structural funds, which is even more difficult to navigate than the research Framework programme.
Nature applauds the commission's hard-fought efforts to prioritize excellence as a key funding criterion -specifically, its plan to devote one-third of the programme to excellent research. This focus will be ever more important if Europe is to compete on the global research stage. Nevertheless, the frustrations of the EU 12 countries need to be addressed, not least because they, along with members of the European Parliament, could delay agreement on the programme plans. This issue is likely to dominate much of the debate on the shape of European funding over the next 18 months. So, let the games begin. ■
Back to the Futures
As Nature's science-fiction column reaches a milestone, we recall some of the highlights.
T his week sees the 400th science-fiction story published in Nature journals under the 'Futures' banner. The number 400 is, of course, only significant to those of us with ten digits. It's more impressive in binary (110010000), although nothing special in Hex (190th) , and the Octalonians of the Octillian system (our keenest readers) will mark it as their 620th.
The number, however presented, includes all the stories we have published in Nature -on, off, simultaneously or instead of -since Arthur C. Clarke's inaugural salvo on 4 November 1999, as well as those featured in the completely separate time-stream of Nature Physics, a few parsecs away.
Looking back at the Futures, as they say, we find that the column, while barely noticed by many, sitting as it does at the back of each printed issue (although free to all online), is a guilty pleasure for the discerning few. The anthology, Futures from Nature, was given a starred review by Publishers Weekly, and, in 2005, the column won Nature the accolade of 'Best Science Fiction Publisher' from the European Science Fiction Society. (We ignore those wags who say that every thing that Nature publishes is science fiction.)
Among the canon of stories published in Futures are missives from superluminaries of the genre: Michael Moorcock, Frederik Pohl and Ursula Le Guin. (Had Isaac Asimov been alive, he' d probably have written the lot.) But there have also been tales from other established writers, perhaps less well known to Nature readers, and many more from scientists -and others -trying out fiction for the very first time. We've had lesbian robots from a senior citizen in Alaska, the shade of Michael Jackson from a virologist in Singapore, the problems of copyrighting dreams from a software consultant in India, and intergalactic country music by a student from Malaysia. Futures was also the venue for the first story ever sold by high-school student Shelly Li of Omaha, Nebraska -who is now just about to publish her first novel. You, too, can join the throng by following the exploits of Futures on Facebook (go.nature.com/mtoodm) or by sending your story (850-950 words) to futures@nature.com. But beware, Futures has become a victim of its own success -like trying to nail jelly to the ceiling, it is now almost as hard to get a story into Futures as to have a research paper published in Nature.
Futures, like radio signals from distant suns, will surely come and go. But as the man said (the 'man' , depending on which web page you read, being Yogi Berra, Niels Bohr, Woody Allen or, who knows, Donald Rumsfeld), prediction is very difficult, especially about the future. As such, we intend to keep Futures until we (or you) get bored of it, or until Earth is struck by an asteroid, whichever comes first. The first seems unlikely. 
